---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-004835"
form_type: "8-K/A"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:49:18.593562+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics FY2022 net loss $128.2M; cash runway to end 2024

## Summary
- Revenue $31.1M in FY2022, down from $45.8M in FY2021 due to Roche agreement termination.
- Net loss $128.2M ($2.62/share) vs. $83.9M ($1.82/share) in FY2021; R&D spend rose to $117.8M.
- Cash, equivalents and marketable securities $337.1M at Dec 31, 2022, down from $451.5M.
- Phase 1 dose escalation data for CFT7455 (MM) and CFT8634 (synovial sarcoma) expected 2H 2023.
- IND submission for CFT8919 (EGFR L858R) on track for 1H 2023; CFT1946 trial dosing patients.

## SEC filing metadata
- accession: 0001628280-23-004835
- form_type: 8-K/A
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828023004835/0001628280-23-004835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828023004835/cccc-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-004835
- JSON: https://secwatch.observer/filing/0001628280-23-004835.json
- Plain text: https://secwatch.observer/filing/0001628280-23-004835.txt

## Key facts
- Earnings Releases
  C4 Therapeutics, Inc. reported the year ended December 31, 2022 results: revenue $31.1 million, net income $128.2 million, EPS $2.62.
  - Period: the year ended December 31, 2022
  - Revenue: $31.1 million
  - Net income: $128.2 million
  - EPS: $2.62
  - Result: reported results
  source text: Revenue: Total revenue for the year ended December 31, 2022 was $31.1 million, compared to $45.8 million for the year ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828023004835/0001628280-23-004835-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.